Shares of Galmed Pharmaceuticals Ltd. (GLMD) are up over 53% at $2.39 today, on news of the company signing a binding term sheet with Czech company Entomus s.r.o.
The term sheet outlines a license agreement for the development and commercialization of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation that allows absorption of sublingually administered GLP-1 drugs.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com